SCHEMBL220265

SCHEMBL220265

CCCCCC(CCCCC)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.70
MAPK1 P28482 1/20 0.70
GRIK1 P39086 2/20 0.67
GRIK2 Q13002 2/20 0.67
SLC1A2 P43004 2/20 0.67
SLC1A1 P43005 2/20 0.67
CHRM1 P11229 1/20 0.67
AKR1A1 P14550 1/20 0.67
CHRM3 P20309 1/20 0.67
HTR2A P28223 1/20 0.67
HTR2C P28335 1/20 0.67
ADRA1A P35348 1/20 0.67
HRH1 P35367 1/20 0.67
DRD3 P35462 1/20 0.67
SLC6A3 Q01959 1/20 0.67
HDAC1 Q13547 1/20 0.67
HDAC2 Q92769 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
GPR84 Q9NQS5 7/20 0.60
FFAR1 O14842 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25293243 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25286597 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25292005 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25295583 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25286591 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25293689 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25292674 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25295689 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25294227 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2
SCHEMBL25292827 0.97 GRIK1 (0.68) CA2MAPK1GRIK1GRIK2SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1046 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108309866-B Adult shower gel containing licorice extract 内蒙古伊草恋生物科技有限责任公司 2022-02-11 CN claimed
EP-3178807-B1 CATIONIC LIPID TAKEDA PHARMACEUTICALS CO (JP) 2020-04-29 EP claimed
JP-4272052-B2 2009-06-03 JP claimed
EP-1419129-B1 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN DPHARM LTD (IL) 2008-12-03 EP claimed
EP-1419129-A4 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN DPHARM LTD (IL) 2006-05-10 EP claimed
JP-2005500305-A 2005-01-06 JP claimed
EP-1419129-A2 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN D-Pharm Limited (IL) 2004-05-19 EP claimed
US-6518311-B2 Analgesics D-PHARM LTD. (IL) 2003-02-11 US claimed
WO-2003000173-A2 USE OF BRANCHED-CHAIN FATTY ACIDS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN D-PHARM LIMITED (IL) 2003-01-03 WO claimed
US-20020042445-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain D-PHARM LTD. (IL) 2002-04-11 US claimed
US-5736503-A High sudsing detergent compositions with specially selected soaps THE PROCTER & GAMBLE COMPANY (US) 1998-04-07 US claimed
EP-0670885-B1 HIGH SUDSING DETERGENT COMPOSITIONS WITH SPECIALLY SELECTED SOAPS PROCTER & GAMBLE (US) 1997-08-20 EP claimed
US-5489393-A NONIONIC SURFACTANT OF REDUCING SUGAR; DISHWASHING AND FABRIC LAUNDERING; ANTISOILANTS THE PROCTER & GAMBLE COMPANY (US) 1996-02-06 US claimed
WO-1995007337-A1 HIGH SUDSING DETERGENT WITH N-ALKOXY POLYHYDROXY FATTY ACID AMIDE AND SECONDARY CARBOXYLATE SURFACTANTS THE PROCTER & GAMBLE COMPANY (US) 1995-03-16 WO claimed
WO-1994012608-A1 HIGH SUDSING DETERGENT COMPOSITIONS WITH SPECIALLY SELECTED SOAPS THE PROCTER & GAMBLE COMPANY (US) 1994-06-09 WO claimed
EP-0249075-B1 AQUEOUS SUSPENSION CONCENTRATE COMPOSITIONS AMERICAN CYANAMID COMPANY (US) 1991-04-10 EP claimed
EP-4737504-A2 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND FORMULATION AND APPLICATION THEREOF Xiamen Sinopeg Biotech Co., Ltd. (CN) 2026-05-06 EP disclosed
EP-4276090-B1 CATIONIC LIPID, LIPOSOME CONTAINING CATIONIC LIPID, AND NUCLEIC-ACID PHARMACEUTICAL COMPOSITION CONTAINING LIPOSOME AND PREPARATION AND APPLICATION THEREOF XIAMEN SINOPEG BIOTECH CO LTD (CN) 2026-04-29 EP disclosed
WO-1994012608-A1 HIGH SUDSING DETERGENT COMPOSITIONS WITH SPECIALLY SELECTED SOAPS THE PROCTER & GAMBLE COMPANY (US) 1994-06-09 WO disclosed
WO-1994000124-A1 GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF WEBER ECKARD (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042445-A1 Use of branched-chain fatty acids and derivatives thereof for the treatment of pain OPRL1, ELOVL5, ELOVL1 CA2 1189/4885MAPK1 2955/4885GRIK1 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.